Aurobindo Pharma announces the completion of CuraTeQ Biologics s.r.o. share transfer from Helix Healthcare B.V. to Curateq Biologics B.V., both wholly owned subsidiaries. The transaction, confirmed by Czech authorities on September 30, 2025, simplifies group ownership.
Source: Aurobindo Pharma Press Release (NSE Exchange Fillings) | Published on Oct 01, 2025
Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.
As quoted in the press release of Aurobindo Pharma (NSE Exchange Filings), Aurobindo Pharma Limited has completed the share transfer of CuraTeQ Biologics s.r.o. from Helix Healthcare B.V. to CuraTeQ Biologics B.V., both wholly owned subsidiaries of Aurobindo. The transfer, the result of an internal reorganisation effort, was completed on September 30, 2025, once the local authorities in the Czech Republic granted their confirmation.
The share transfer was first disclosed on July 29, 2025, via a binding agreement to complete the shares by November 30, 2025. However, completion was reached sooner, providing a much more efficient corporate structure from Aurobindo’s point of view with respect to its biologics business position for Curateq Biologics B.V. to be the direct owner of CuraTeQ Biologics s.r.o.
Also read: Lupin secures US FDA approval for Rivaroxaban oral suspension
Aurobindo Pharma completes share transfer of CuraTeQ Biologics s.r.o. from Helix Healthcare B.V. to Curateq Biologics B.V.
The transfer was confirmed by Czech authorities on September 30, 2025.
Both entities involved are wholly owned subsidiaries of Aurobindo Pharma.
The restructuring simplifies the company’s biologics ownership structure.
The original binding agreement was signed on July 29, 2025.
Also read: Swan Defence partners with Samsung for shipbuilding collaboration
This internal transfer does not alter the ultimate ownership of CuraTeQ Biologics, but does simplify the organisational structure of Aurobindo Pharma’s biologics vertical. The internal transfer means Curateq Biologics B.V. now directly controls CuraTeQ Biologics s.r.o. This creates operational flow of management and provides for enhanced operational integration in the biologics vertical.
As of October 1, 2025, at 2:10 PM IST, Aurobindo Pharma share price stands at ₹1,108.25 per share on the BSE, up by ₹4.70 or 0.42% from the previous session.
Also read: RITES inks MoU with Etihad Rail to boost UAE infrastructure ties
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading